These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 36161830)

  • 21. Panretinal Photocoagulation for Diabetic Retinopathy in the RIDE and RISE Trials: Not "1 and Done".
    Gonzalez VH; Wang PW; Ruiz CQ
    Ophthalmology; 2021 Oct; 128(10):1448-1457. PubMed ID: 31668888
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Functional outcomes of sustained improvement on Diabetic Retinopathy Severity Scale with intravitreal aflibercept in the VISTA and VIVID trials.
    Dhoot DS; Moini H; Reed K; Du W; Vitti R; Berliner AJ; Singh RP
    Eye (Lond); 2023 Jul; 37(10):2020-2025. PubMed ID: 35440699
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema.
    Mitchell P; Bandello F; Schmidt-Erfurth U; Lang GE; Massin P; Schlingemann RO; Sutter F; Simader C; Burian G; Gerstner O; Weichselberger A;
    Ophthalmology; 2011 Apr; 118(4):615-25. PubMed ID: 21459215
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy.
    Ip MS; Domalpally A; Sun JK; Ehrlich JS
    Ophthalmology; 2015 Feb; 122(2):367-74. PubMed ID: 25439595
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The RELATION study: efficacy and safety of ranibizumab combined with laser photocoagulation treatment versus laser monotherapy in NPDR and PDR patients with diabetic macular oedema.
    Lang GE; Liakopoulos S; Vögeler J; Weiß C; Spital G; Gamulescu MA; Lohmann C; Wiedemann P
    Acta Ophthalmol; 2018 May; 96(3):e377-e385. PubMed ID: 29090846
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Aflibercept on Diabetic Retinopathy Severity and Visual Function in the RECOVERY Study for Proliferative Diabetic Retinopathy.
    Alagorie AR; Velaga S; Nittala MG; Yu HJ; Wykoff CC; Sadda SR
    Ophthalmol Retina; 2021 May; 5(5):409-419. PubMed ID: 32882447
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravitreal conbercept for diabetic macular oedema: 2-year results from a randomised controlled trial and open-label extension study.
    Liu K; Wang H; He W; Ye J; Song Y; Wang Y; Liu X; Wu Z; Chen S; Fan K; Liu Y; Zhang F; Li Z; Liu L; Zhang J; Zhang X; Ye J; Liang X; Li X; Ke X; Wu Q; Li J; Tao S; Wang X; Rosenfeld P; Heier JS; Kaiser P; Xu X
    Br J Ophthalmol; 2022 Oct; 106(10):1436-1443. PubMed ID: 34001667
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial.
    Sahni J; Patel SS; Dugel PU; Khanani AM; Jhaveri CD; Wykoff CC; Hershberger VS; Pauly-Evers M; Sadikhov S; Szczesny P; Schwab D; Nogoceke E; Osborne A; Weikert R; Fauser S
    Ophthalmology; 2019 Aug; 126(8):1155-1170. PubMed ID: 30905643
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravitreal aflibercept for diabetic macular oedema in real-world: 36-month visual acuity and anatomical outcomes.
    Lukic M; Williams G; Shalchi Z; Patel PJ; Hykin PG; Hamilton RD; Rajendram R
    Eur J Ophthalmol; 2021 May; 31(3):1201-1207. PubMed ID: 32429690
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study.
    Prünte C; Fajnkuchen F; Mahmood S; Ricci F; Hatz K; Studnička J; Bezlyak V; Parikh S; Stubbings WJ; Wenzel A; Figueira J;
    Br J Ophthalmol; 2016 Jun; 100(6):787-95. PubMed ID: 26453639
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Baseline Factors Affecting Changes in Diabetic Retinopathy Severity Scale Score After Intravitreal Aflibercept or Laser for Diabetic Macular Edema: Post Hoc Analyses from VISTA and VIVID.
    Dhoot DS; Baker K; Saroj N; Vitti R; Berliner AJ; Metzig C; Thompson D; Singh RP
    Ophthalmology; 2018 Jan; 125(1):51-56. PubMed ID: 28764888
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term effects of ranibizumab on diabetic retinopathy severity and progression.
    Ip MS; Domalpally A; Hopkins JJ; Wong P; Ehrlich JS
    Arch Ophthalmol; 2012 Sep; 130(9):1145-52. PubMed ID: 22965590
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-Time Photographic- and Fluorescein Angiographic-Guided Management of Diabetic Retinopathy: Randomized PRIME Trial Outcomes.
    Yu HJ; Ehlers JP; Sevgi DD; Hach J; O'Connell M; Reese JL; Srivastava SK; Wykoff CC
    Am J Ophthalmol; 2021 Jun; 226():126-136. PubMed ID: 33529593
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-Term Vision Outcomes in Patients With DME and a Limited Early Visual Response to Ranibizumab in RIDE and RISE.
    Singh RP; Pieramici DJ; Wang PW; Gune S
    Ophthalmic Surg Lasers Imaging Retina; 2020 Apr; 51(4):210-218. PubMed ID: 32348537
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ranibizumab 0.5 mg for Diabetic Macular Edema with Bimonthly Monitoring after a Phase of Initial Treatment: 18-Month, Multicenter, Phase IIIB RELIGHT Study.
    Pearce I; Banerjee S; Burton BJ; Chakravarthy U; Downey L; Gale RP; Gibson J; Pagliarini S; Patel J; Sivaprasad S; Andrews C; Brittain C; Warburton J;
    Ophthalmology; 2015 Sep; 122(9):1811-9. PubMed ID: 26150052
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictors of Early Diabetic Retinopathy Regression with Ranibizumab in the RIDE and RISE Clinical Trials.
    Singer M; Liu M; Schlottmann PG; Khanani AM; Hemphill M; Hill L; Tuomi L; Haskova Z
    Clin Ophthalmol; 2020; 14():1629-1639. PubMed ID: 32606578
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of intravitreal ranibizumab on retinal hard exudate in diabetic macular edema: findings from the RIDE and RISE phase III clinical trials.
    Domalpally A; Ip MS; Ehrlich JS
    Ophthalmology; 2015 Apr; 122(4):779-86. PubMed ID: 25601535
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-life anti-vascular endothelial growth factor treatment for age-related macular degeneration and diabetic macular edema in an Italian tertiary referral hospital.
    Battaglia Parodi M; Romano F; Arrigo A; Sacchi R; Scanzi G; Ferri C; Bandello F
    Eur J Ophthalmol; 2020 Nov; 30(6):1461-1466. PubMed ID: 31617403
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patterns of Early and Delayed Visual Response to Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration.
    Stoller GL; Kokame GT; Dreyer RF; Shapiro H; Tuomi LL
    JAMA Ophthalmol; 2016 May; 134(5):545-553. PubMed ID: 27010625
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparing the Efficacy of Bevacizumab and Ranibizumab in Patients with Diabetic Macular Edema (BRDME): The BRDME Study, a Randomized Trial.
    Vader MJC; Schauwvlieghe AME; Verbraak FD; Dijkman G; Hooymans JMM; Los LI; Zwinderman AH; Peto T; Hoyng CB; van Leeuwen R; Vingerling JR; Moll AC; van Lith-Verhoeven JJC; Dijkgraaf MGW; Schlingemann RO;
    Ophthalmol Retina; 2020 Aug; 4(8):777-788. PubMed ID: 32362552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.